Taiwan Tfda Medical Device Registration Service For IVD Device
A Taiwan TFDA medical device registration service for an in-vitro diagnostic (IVD) should produce a defensible filing route, a responsible Taiwanese applicant, an evidence-indexed dossier and an auditable response process. An IVD may be a reagent, analyser, software or system examining human specimens. A foreign CE mark or FDA clearance alone does not determine its Taiwan class or replace the applicable Taiwan filing.
Select the correct TFDA route before filing
| Filing route | When and what to file |
|---|---|
| Class I: notified listing item | If the precise classification item is announced for listing, the eligible medical-device firm records the required product/manufacturer details and uploads the applicable material in the TFDA listing system. Obtain the listing number; check the subsequent annual-declaration duty. |
| Class I: licence route | A Class I IVD not covered by a listing announcement may require an application under Article 5 and Appendix 1. Do not assume that every low-risk test can be listed. |
| Class II or III: licence application | Apply for registration and market approval under Article 6 and Appendix 2, with Appendix 3 relevant to qualifying Class II conformity declarations. Determine the Taiwan classification code and whether a licensed local predicate exists; the required evidence depends on the exact IVD and any applicable notices. |
Before selecting a row, freeze the claimed analyte, specimen, users (professional or home), patient population, test setting, qualitative/quantitative output and medical decisions supported. Check the Taiwanese classification annex and TFDA device database. If status or class remains uncertain, ask TFDA for a formal product-attribute/classification assessment. The applicable route is product-specific, not a blanket IVD exemption.
Applicant, manufacturer and QSD: allocate responsibility
- Taiwan applicant: for an imported IVD, appoint an appropriately licensed Taiwanese medical-device firm to submit or maintain the filing. Verify the medical-device business permit and import scope. Record who holds the product licence or listing and who is authorized to import; a commercial distributor is not automatically the registration holder.
- Foreign manufacturer: supply an original manufacturer authorization that matches manufacturer, Taiwan applicant, product names and models; provide the country-of-origin manufacture/free-sale evidence when the applicable appendix requires it. Resolve any discrepancy between the authorization, certificate, instructions and dossier before submission.
- Quality-system workstream: separately confirm whether the foreign manufacturing site requires QSD conformity assessment/manufacturing authorization or falls within an officially announced exemption or alternative mode. This is not the product licence. Assign a site-document owner and track the QSD application through its dedicated online platform.
Build an IVD-specific dossier, not a generic device file
- Identity and scope — Taiwan classification item, Chinese/English product names, analyte and indication, specimen matrix, intended user and setting, full model/reagent/analyser/software configuration; record whether kits, accessories or variants belong in the same application.
- Applicant and origin — Taiwanese firm permit, signed manufacturer authorization, manufacture/free-sale certificates for imported products when required, manufacturing-site identity and applicable QSD documentation. Match names and addresses character by character.
- Technical characteristics — operating principle, assay workflow, constituents, equipment interfaces, calibrators, controls, software version, analytical measurement range, cut-off logic, intended results and limitations. State which versions and configurations the evidence covers.
- Performance package — as applicable, analytical sensitivity/detection limit, specificity/cross-reactivity, accuracy or agreement, repeatability/reproducibility, interference, specimen stability, lot-to-lot variation, clinical-performance evidence and reference-method comparisons; include protocols, acceptance criteria, raw or traceable results.
- Labelling and instructions — drafts of labels, packaging and instructions aligned to approved claims, including appropriate Traditional Chinese text for Taiwan. Check specimen instructions, user qualifications, precautions, interpretation, storage and expiry, and reconcile translations against original IFU.
- Submission map — current TFDA form and appendices, indexed sections/page references, product comparison or locally approved predicate where relevant, missing-evidence log, responsible owner and final sign-off. Do not treat an overseas approval as a substitute for a Taiwan-specific review.
Submission and authority-review workflow
- Lock the IVD claims, exact classification item, licence versus listing route and grouping of model variants; obtain written internal approval of the regulatory position.
- Verify the Taiwanese applicant’s permit, manufacturer authorization and import authority; identify the QSD/manufacturing-permit pathway and any announced exception.
- Build the administrative documents, Traditional Chinese labelling drafts and the IVD-specific technical/performance index; resolve inconsistencies before filing.
- Select the submission channel for the actual application type. TFDA permits electronic, postal or counter routes for certain Class II/III submissions; since 1 July 2025 specific categories require electronic submission, subject to an official paper exception. Class I listing uses its own system.
- Pay applicable official fees, register the submission receipt, and monitor formal review and substantive review. Under Articles 7–8, a correction notice ordinarily allows one month at formal review and three months at substantive review; observe the actual notice and any special procedure.
- Answer each deficiency point with a response matrix and updated controlled documents. After approval, complete TFDA-issued licence collection requirements and reconcile final approved Chinese/English names, models and instructions before distribution.
Rejection and delay triggers: a practical control table
| Potential problem | Control before or during review |
|---|---|
| Wrong route or inconsistent IVD claim | Compare the classification code with the intended use, home-use claim, specimen and assay principle before upload; request authority assessment if unresolved. |
| Authorization, free-sale or QSD mismatch | Reconcile legal entities, factory addresses, model identifiers and document validity; do not equate an ISO certificate with Taiwan approval. |
| Incomplete analytical/clinical evidence | Map each performance claim to test protocols, results, acceptance criteria and exact model/lot; justify gaps and predicate comparisons. |
| Wrong channel or unanswered deficiency | Check whether the case falls in a mandatory e-filing category and calendar TFDA response dates; a mandatory electronic case sent on paper without approval may fail formal review. |
After authorization: maintain the approved IVD scope
- Licence changes: assess alterations to analyte, indication, cut-offs, components, software, models, manufacturing site or approved labelling against the change rules before implementation; some changes need a TFDA application while limited label changes may be documented internally.
- Licence extension: for a licence subject to renewal, Article 17 provides an application window within six months before expiry; missed renewal can require re-application. Track product and QSD/manufacturing permissions separately.
- Listed items: maintain listing details and complete any applicable annual declaration; a listing number is not the same document as a product licence.
- Market control: implement complaint handling, traceability, adverse-event or field-action processes and Taiwan-specific labelling/distribution rules as applicable. Check current announcements rather than assuming every obligation applies to every IVD.
This page covers execution of a specific IVD filing. For the wider cross-product service pathway see the general TFDA registration service; for classification strategy, uncertainty and regulatory gap assessment before choosing a filing see the TFDA registration consultant. A practical first hand-off is the intended-use/assay description, variant list, Taiwan applicant details, existing certificates, IFU and test matrix—not a promise of approval or fixed timing.
Official regulatory sources
Questions specific to Taiwan IVD filings
Can I use an EU IVDR certificate or US FDA clearance instead of a TFDA licence?
No automatic substitution follows. Foreign evidence may help support the dossier, but the Taiwan classification, listing or licence route and applicable product evidence must be determined independently.
Is every Class I IVD only listed online?
No. Listing applies to officially announced items; another Class I item may follow the licence route. Check the precise Taiwan item and the current announcement before preparing the form.
Who can submit for a manufacturer outside Taiwan?
An appropriately permitted Taiwan medical-device firm should be identified as the applicant/holder for the imported IVD. Confirm the manufacturer authorization and import authorization rather than assuming any reseller can file.
Does one registration cover a reader, several reagents and home-use claims?
Not necessarily. Separate intended uses, classification codes, product names, accessories, test settings or configurations may change the filing scope. Document the grouping rationale and confirm it before submission.
What if TFDA requests more data on sensitivity or clinical performance?
Use the review notice to build a numbered deficiency-response matrix; provide relevant validation and traceable results for the exact claimed use, address revised IFU/labels, and meet the stated response deadline.